Our investigation revealed that treatment with two lysosomal inhibitors, chloroquine (CQ) and NH4Cl reversed shPrp19-induced degradation of CDC5L in GC cells, whereas two proteasome inhibitors, carfilzomib (CFZ) and MG132 failed to support this effect (Fig. 5K-L), indicating that Prp19 may regulate CDC5L abundance via the lysosome pathway in GC cells. This evidence concerns the gene CDC5L and gastric cancer.